摘要目的 观察多西他赛联合奥沙利铂二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效及毒副反应,并进行安全评估.方法 52例一线治疗失败的晚期非小细胞肺癌患者采用多两他赛+奥沙利铂化疗3周期后,用世界卫生组织(WHO)的疗效及抗肿瘤药物急性及亚急性毒性反应分度评价疗效和毒性.结果 52例患者均完成3周期以上化疗,完全缓解(CR)4例,部分缓解(PR)12例,总有效率30.8%,不良反应主要表现为骨髓抑制、脱发及消化道反应等,未见水钠潴留.结论 多西他赛联合奥沙利铂治疗一线化疗失败的非小细胞肺癌疗效确切,可以提高生活质量,毒副反应较轻,耐受性好,值得临床进一步推广研究.

abstractsObjective To evaluate the efficacy and toxicity of docetaxel plus oxaliplatin as the second line therapy for with advanced non-small cell lung cancer(NSCLC),and to investigate whether these two regimens result in similar outcomes.Methods Fifry-two NSCLC patients who had failed in first-line chemotherapy received docetacel and oxaliplatin chem.othempy,totally three cycles.The respond and toxicity were evaluated using World Health Organization toxicity scale.Results Among 52 patients.four patients received complete respond(CR) and twelve patients had partial respond(PR).The overall rate(RR) was 30.8%.The most frequent toxicities were neutropenia,leucopenia and gastrointestinal symptoms.Other toxicities such as alopecia and vomiting were mild and generajlv well tolcrated.No fluid retention was noticed.Conclusion The combination chemotherapy of docetaxel and oxaliplatin as primary therapy for pmiems with NSCLC who have failed precious platiBum-based chemotherapy is effective and well-tolerated.It may remarkably improve quailty of life and be worthy to further clinical trial.